| 摘要 |
The oral pharmaceutical composition comprises a H+, K+-ATPase inhibitor of formula I Het1-X-S(O)-Het2 wherein Het1 is a group of formula A, Het2 is a group of formula B and X is a group of formula D which gives an extended blood plasma of a H+, K+-ATPase inhibitor of formula I. In formulae A, B and D: the N in the benzimidazole moiety means that one of the ring carbon atoms substituted by R6 to R9 may be exchanged for a nitrogen atom without any substituents; R1 to R3 are independently H, alkyl, alkoxy optionally substituted by F, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl or phenylalkoxy; R4 and R5 are independently H, alkyl or alkoxy; R6 to R9 are independently H, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, oxazolyl, trifluoroalkyl or adjacent groups of R6 to R9 form ring structures that may be further substituted; R10 is H or forms an alkylene chain with R3 and R11 and R12 are independently H, halo or alkyl.
|
